Jae‐Lyun Lee

机构：Ulsan College, Korea Advanced Institute of Science and Technology, Asan Medical Center, University of Ulsan, St Pancras Hospital, The Catholic University of Korea Seoul St. Mary's Hospital · ORCID：0000-0002-9420-7162

发表论文 642 篇 · 总被引 26878 次 · h-index 67

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 117)
• Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study (2025 · The Lancet Oncology · 被引 26)
• First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial (2025 · European Urology · 被引 13)
• Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma. (2025 · Journal of Clinical Oncology · 被引 6)
• Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). (2025 · Journal of Clinical Oncology · 被引 5)
• Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 3)